<DOC>
	<DOCNO>NCT01120691</DOCNO>
	<brief_summary>This study design assess effect once-daily QVA149 COPD exacerbation patient severe severe COPD .</brief_summary>
	<brief_title>Effect QVA149 Versus NVA237 Tiotropium Chronic Obstructive Pulmonary Disorder ( COPD ) Exacerbations</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion Criteria : 1 . Male female adult age ≥40 year , sign informed consent form prior initiation studyrelated procedure . 2 . Patients severe severe Chronic Obstructive Pulmonary Disease COPD ( Stage III IV ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines 2008 . 3 . Current exsmokers smoke history least 10 pack year ( Ten packyears define 20 cigarette day 10 year , 10 cigarette day 20 year ) . 4 . Patients postbronchodilator Forced Expiratory Volume one second ( FEV1 ) &lt; 50 % predict normal value , postbronchodilator FEV1/ Forced Vital Capacity ( FVC ) &lt; 0.70 Visit 2 ( day 14 ) . ( Post refers 1 h sequential inhalation 84 µg ( equivalent dose ) ipratropium bromide 400 µg salbutamol ) . 5 . A documented history least 1 COPD exacerbation previous 12 month require treatment systemic glucocorticosteroids and/or antibiotic . 1 . Pregnant woman nurse mother ( pregnancy confirm positive urine pregnancy test ) . 2 . Women childbearing potential 3 . Patients require long term oxygen therapy ( &gt; 15 h day ) daily basis chronic hypoxemia . 4 . Patients COPD exacerbation require treatment antibiotic , systemic steroid ( oral intravenous ) hospitalization 6 week prior visit 1 visit 1 ( Day 21 ) Visit 3 ( Day 1 ) . 5 . Patients develop COPD exacerbation period visit 1 3 ineligible permit rescreened minimum 6 week resolution COPD exacerbation . 6 . Patients respiratory tract infection within 4 week prior visit 1 ( Day 21 ) • Patients develop upper low respiratory tract infection screen period ( visit 3 ( Day 1 ) eligible , permit rescreened 4 week resolution respiratory tract infection 7 . Patients concomitant pulmonary disease , e.g . pulmonary tuberculosis ( unless confirm chest xray longer active ) , clinically significant bronchiectasis , sarcoidosis , interstitial lung disorder pulmonary hypertension . 8 . Patients lung lobectomy , lung volume reduction lung transplantation . 9 . Patients , judgment investigator , clinically relevant laboratory abnormality clinically significant condition ( limited ) : Unstable ischemic heart disease , leave ventricular failure , history myocardial infarction , arrhythmia ( exclude chronic stable Atrial Fibrillation ( AF ) . Patients event consider clinically significant investigator may consider inclusion study history malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin uncontrolled hypo hyperthyroidism , hypokalemia hyper adrenergic state narrowangle glaucoma Symptomatic prostatic hyperplasia bladderneck obstruction moderate severe renal impairment urinary retention . ( Patients Transurethral Resection Prostate ( TURP ) exclude study . Patients underwent full resection prostate could consider study , well patient asymptomatic stable pharmacological treatment condition ) . condition might compromise patient safety compliance , interfered evaluation , preclude completion study 10 . Patients history asthma indicate ( limited ) blood eosinophil count &gt; 600/mm3 ( visit 2 ) , onset symptom prior 40 year . Patients without asthma exclude eosinophil count &gt; 600/mm3 visit 2 . 11 . Patients allergic rhinitis use H1 antagonists intranasal corticosteroid intermittently ( treatment constant dose permit ) . 12 . Patients eczema ( atopic ) , know high immunoglobulin E ( IgE ) level know positive skin prick test last 5 year . 13 . Patients known history diagnosis alpha1 antitrypsin deficiency . 14 . Patients participate active phase supervise pulmonary rehabilitation program . 15 . Patients Type I uncontrolled Type II diabetes . 16 . Patients contraindicate treatment , history reactions/ hypersensitivity follow inhaled drug drug similar class component thereof : anticholinergic agent long short act beta2 agonist sympathomimetic amine . 17 . Patients history long QT syndrome whose corrected QT interval ( QTc ) measure visit 2 ( Day 14 ) ( Fridericia method ) prolong ( &gt; 450 m male female ) confirm central ECG assessor . 18 . Patients clinically significant abnormality screen baseline ECG judgment investigator would potential risk enrol study . ( These patient could rescreened ) . 19 . Patients need treatment COPD ally condition start study ( visit 1 ) 20 . Patients need treatment COPD ally condition ( e.g . allergic rhinitis ) unless stabilize 21 . Patients take prohibited medication 22 . Patients unable use dry powder inhaler ( e.g . single dose dry powder inhaler ( SDDPI ) , HandiHaler® device , pressurize Metered Dose Inhaler ( MDI ) ( rescue medication ) . 23 . Patients unable use electronic patient diary . 24 . Patients , opinion investigator know unreliable noncompliant . 25 . Patients use investigational drug time enrollment , within 30 day 5 halflives visit 1 ( day 21 ) , whichever longer . 26 . Patients live attenuate vaccination within 30 day prior screen visit runin period . Inactivated influenza vaccination , pneumococcal vaccination inactivate vaccine acceptable provide administer within 48 hour prior screen randomization visit . No additional exclusion apply investigator , order ensure study population representative eligible patient .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>QVA149</keyword>
	<keyword>NVA237</keyword>
	<keyword>COPD</keyword>
	<keyword>exacerbation</keyword>
	<keyword>combination bronchodilator</keyword>
</DOC>